biostudies-literatureUnknown103(7)Kiladjian JJAOP HealthInterferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim to normalize hematological parameters and reduce the thrombotic risk, but they do not modify the natural history of the disease and hence, have no impact on disease progression. Ropeginterferon alfa-2b (trade name BESREMi®), a novel, monopegylated interferon alfa-2b with an extended administration interval, has demonstrated a robust and sustained efficacy in polycythemia vera (PV) patients. Given the similarities in disease pathophysiology and treatment goals, ropeginterferon alfa-2b holds promise as a treatment option for ET. The ROP-ET trial is a prospective, multicenter,Annals of hematology2299-2310https://www.ebi.ac.uk/biostudies/studies/S-EPMC11224110biostudies-literatureROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.PMC11224110Kiladjian JJCrisan AMMayer JAl-Ali HKJames CCerna OTerpos EDe Stefano VDanaila CDHeidel FHGarcia-Gutierrez VIlles ABreccia MDohner KGora-Tybor JKrejcy KPalandri FSchmidt SAlvarez-Larran ABeggiato EReiter AJGuglielmelli PKoschmieder STomuleasa CKlade CGrosicki SMarin FFLazaroiu MCNagy ZGCirici BXUnger MSacha TGriesshammer MKrauth MTPappa VNicolini FEBuxhofer-Ausch VSchlager SWolfler ABieniaszewska MEmpson VfalseROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim to normalize hematological parameters and reduce the thrombotic risk, but they do not modify the natural history of the disease and hence, have no impact on disease progression. Ropeginterferon alfa-2b (trade name BESREMi®), a novel, monopegylated interferon alfa-2b with an extended administration interval, has demonstrated a robust and sustained efficacy in polycythemia vera (PV) patients. Given the similarities in disease pathophysiology and treatment goals, ropeginterferon alfa-2b holds promise as a treatment option for ET. The ROP-ET trial is a prospective, multicenter,2024-01-01T00:00:00Z2024 Jul2026-06-02T21:18:43.332Z2025-04-04T12:21:38.724ZS-EPMC112241103843862710.1007/s00277-024-05665-4